Q-omics provides the consensus-scored ERICH2 profile across patient tissues and cancer cell-line models. ERICH2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ERICH2 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, ERICH2 RNA expression shows 14,372 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, COAD, and ESCA as cancer lineages where ERICH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERICH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERICH2 survival associations across molecular data types. ERICH2 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERICH2 RNA expression–survival associations across cancer types. High ERICH2 expression shows unfavorable associations in KIRP, KICH, CESC, LGG and LIHC, but favorable associations in MESO. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ERICH2 RNA expression.
This table summarizes ERICH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ERICH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERICH2 shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in COAD, LIHC and BRCA. The COAD box plot shows higher ERICH2 RNA expression in tumor versus normal tissue (log2 FC = +1.424, t-test p < 0.001).
This table shows molecular features associated with ERICH2 in patient tissues and cancer cell lines. In patient samples, ERICH2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ERICH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
